Patient Preference and Adherence (Aug 2024)
Treatment Preferences Among Patients with Renal Cell Carcinoma: Results from a Discrete Choice Experiment
Abstract
Moshe C Ornstein,1 Lisa C Rosenblatt,2 Xin Yin,2 Viviana Del Tejo,2 Sarah B Guttenplan,2 Flavia Ejzykowicz,2 Kathleen Beusterien,3 Oliver Will,3 deMauri S Mackie,3 Grace Skiles,3 Marc DeCongelio3 1Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA; 2Global HEOR Oncology, Bristol Myers Squibb, Princeton, NJ, USA; 3Real World Evidence, Oracle Life Sciences, Austin, TX, USACorrespondence: Marc DeCongelio, Oracle Life Sciences, 2800 Rock Creek Parkway, North Kansas City, MO, 64117, USA, Tel +18162011975, Email [email protected]: The treatment landscape for advanced/metastatic renal cell carcinoma (aRCC) has evolved quickly with the introduction of immunotherapies as a first-line treatment option. This study examined the preferences of patients with aRCC to better understand the characteristics of preferred treatments and the tradeoffs patients are willing to make when choosing treatment.Methods and Materials: An online, cross-sectional survey was conducted in the US from May to August 2022 with adult patients with aRCC. A discrete-choice experiment assessed treatment preferences for aRCC. Attributes were identified through literature review and qualitative interviews and included progression-free survival, survival time, objective response rate, duration of response, risk of serious side effects, quality of life (QoL), and treatment regimen.Results: Survey results from 299 patients with aRCC were analyzed. Patients had a mean age of 55.7 years, were primarily White (50.5%) and were evenly representative of males (49.8%) and females (48.8%). Improvements in all attributes influenced treatment choice. On average, increasing survival time from 10% to 55% was most important, followed by improvements in QoL (ie, from worsens a lot to improves) and improvements to treatment regimen convenience (ie, less frequent infusions). Risk of serious adverse events and increased progression-free time, objective response rate (ORR), and duration of response (DOR) were of lesser importance.Conclusion: In this study, patients highlighted that improving survival time was the most important and that QoL is also an important consideration. Discussions during treatment decision-making may benefit from broader conversations around treatment characteristics, including impacts on QoL and convenience of the regimen.Keywords: discrete choice experiment, patient preference, treatment preference, renal cell carcinoma
